[
    [
        {
            "time": "",
            "orginal_text": "深读复星：产业大生态和投资大风口",
            "features": {
                "keywords": [
                    "复星",
                    "产业大生态",
                    "投资大风口"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "深读复星：产业大生态和投资大风口",
            "scores": {
                "News_content": "深读复星：产业大生态和投资大风口",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "【安信非银】复星国际年报点评：生态布局初显成效，投资聚焦注重科创",
            "features": {
                "keywords": [
                    "复星国际",
                    "生态布局",
                    "投资聚焦",
                    "科创"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【安信非银】复星国际年报点评：生态布局初显成效，投资聚焦注重科创",
            "scores": {
                "News_content": "【安信非银】复星国际年报点评：生态布局初显成效，投资聚焦注重科创",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "复星国际去年营收首破千亿元 郭广昌：投资将以控股型为主",
            "features": {
                "keywords": [
                    "复星国际",
                    "营收",
                    "控股型投资"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "复星国际去年营收首破千亿元 郭广昌：投资将以控股型为主",
            "scores": {
                "News_content": "复星国际去年营收首破千亿元 郭广昌：投资将以控股型为主",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "【国信医药|年报点评】复星医药（600196.SH）：利润触底回升，生物药扬帆起航",
            "features": {
                "keywords": [
                    "复星医药",
                    "利润触底回升",
                    "生物药"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【国信医药|年报点评】复星医药（600196.SH）：利润触底回升，生物药扬帆起航",
            "scores": {
                "News_content": "【国信医药|年报点评】复星医药（600196.SH）：利润触底回升，生物药扬帆起航",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "医疗保健：科技创新将成为主旋律 荐6股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "科技创新"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医疗保健：科技创新将成为主旋律 荐6股",
            "scores": {
                "News_content": "医疗保健：科技创新将成为主旋律 荐6股",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "2019中国创新药全球化布局 信达等企业取得突破性进展",
            "features": {
                "keywords": [
                    "创新药",
                    "全球化布局",
                    "信达"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "2019中国创新药全球化布局 信达等企业取得突破性进展",
            "scores": {
                "News_content": "2019中国创新药全球化布局 信达等企业取得突破性进展",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "orginal_text": "【国金研究】保险资金专题：险资如何配置A股及其相关特征",
            "features": {
                "keywords": [
                    "保险资金",
                    "A股配置"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "保险"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "【国金研究】保险资金专题：险资如何配置A股及其相关特征",
            "scores": {
                "News_content": "【国金研究】保险资金专题：险资如何配置A股及其相关特征",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药净利润下滑 研发费用上升投资收益减少是主因？ 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利润下滑",
                    "研发费用",
                    "投资收益减少"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "复星医药净利润下滑 研发费用上升投资收益减少是主因？ 盈利能力下降",
            "scores": {
                "News_content": "复星医药净利润下滑 研发费用上升投资收益减少是主因？ 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药去年净利27.08亿同比减13% 董事长陈启宇年薪1425万元 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利下降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "复星医药去年净利27.08亿同比减13% 董事长陈启宇年薪1425万元 盈利能力下降",
            "scores": {
                "News_content": "复星医药去年净利27.08亿同比减13% 董事长陈启宇年薪1425万元 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "2018年复星国际总收入首破千亿元，投资近半数是海外项目",
            "features": {
                "keywords": [
                    "复星国际",
                    "总收入",
                    "海外项目"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "2018年复星国际总收入首破千亿元，投资近半数是海外项目",
            "scores": {
                "News_content": "2018年复星国际总收入首破千亿元，投资近半数是海外项目",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药CEO吴以芳：复宏汉霖H股上市策略不变 正认真研究科创板",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "H股上市",
                    "科创板"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "复星医药CEO吴以芳：复宏汉霖H股上市策略不变 正认真研究科创板",
            "scores": {
                "News_content": "复星医药CEO吴以芳：复宏汉霖H股上市策略不变 正认真研究科创板",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "遇研发阵痛 复星医药四年来净利首次下滑 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "研发阵痛",
                    "净利下滑",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "遇研发阵痛 复星医药四年来净利首次下滑 盈利能力下降",
            "scores": {
                "News_content": "遇研发阵痛 复星医药四年来净利首次下滑 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]